Molecules, Vol. 28, Pages 5468: Design and Synthesis of AMPK Activators and GDF15 Inducers

Molecules, Vol. 28, Pages 5468: Design and Synthesis of AMPK Activators and GDF15 Inducers

Molecules doi: 10.3390/molecules28145468

Authors: Meijian Zhang Andrea Bagán Donna Martínez Emma Barroso Xavier Palomer Santiago Vázquez Carmen Escolano Manuel Vázquez-Carrera

Targeting growth differentiation factor 15 (GDF15) is a recent strategy for the treatment of obesity and type 2 diabetes mellitus (T2DM). Here, we designed, synthesized, and pharmacologically evaluated in vitro a novel series of AMPK activators to upregulate GDF15 levels. These compounds were structurally based on the (1-dibenzylamino-3-phenoxy)propan-2-ol structure of the orphan ubiquitin E3 ligase subunit protein Fbxo48 inhibitor, BC1618. This molecule showed a better potency than metformin, increasing GDF15 mRNA levels in human Huh-7 hepatic cells. Based on BC1618, structural modifications have been performed to create a collection of diversely substituted new molecules. Of the thirty-five new compounds evaluated, compound 21 showed a higher increase in GDF15 mRNA levels compared with BC1618. Metformin, BC1618, and compound 21 increased phosphorylated AMPK, but only 21 increased GDF15 protein levels. Overall, these findings indicate that 21 has a unique capacity to increase GDF15 protein levels in human hepatic cells compared with metformin and BC1618.